Developing an encapsulated inactivated H1N1 influenza vaccine

1997 1997

Other formats: Order a copy

Abstract (summary)

The purpose of this study was to evaluate the efficacy of an alginate encapsulated formalin inactivated influenza virus vaccine in mice. Currently approved parenteral vaccines provide protection of the lower respiratory against pneumonia, a common complication of influenza virus infection. However, upper respiratory tract infections still occur, despite vaccination. Protection of the upper respiratory tract would likely be better elicited by vaccinating via a mucosal route. In this study, mice vaccinated subcutaneously with alginate encapsulated virus mounted an antigen specific systemic antibody and lymphocyte proliferative response, even following simulated gastric juice pretreatment of the vaccine. The antibodies produced in response to the encapsulated virus were shown to inhibit hemagglutination induced by influenza virus, similar to that stimulated by nonencapsulated virus. Mice vaccinated orally with encapsulated virus mounted a less vigorous immune than mice vaccinated subcutaneously, but were significantly protected against challenge with virulent H1N1 influenza virus, as compared to negative control vaccinees, as lower titers of live virus were recovered from the lungs and tracheas of vaccinated mice than the controls. Coencapsulation of the mucosal immune adjuvant cholera toxin did not enhance the response to orally administered encapsulated virus, but did increase the immunoglobulin A response to nonencapsulated virus administered orally, and increased the degree to which nonencapsulated virus vaccinees were protected against virulent challenge. While the loading efficiency of the alginate microparticles with various test antigens was shown to be enhanced by zinc ions, the immune response in mice vaccinated subcutaneously with influenza virus that was encapsulated in the presence of calcium only, 0.5% (w/v) calcium chloride with 0.05% zinc chloride, or saturated calcium chloride and zinc chloride solution mounted nearly identical immune responses. As parenterally administered encapsulated virus was shown to be immunogenic, modifications are suggested to potentially enhance the uptake of virus loaded microparticles from the intestinal tract following oral administration.

Indexing (details)

0982: Immunology
0410: Microbiology
0572: Pharmaceuticals
Identifier / keyword
Health and environmental sciences; Biological sciences; Alginate; Encapsulated; H1N1; Influenza vaccine; Mucosal vaccines; Oral delivery
Developing an encapsulated inactivated H1N1 influenza vaccine
Woodyard, Leszlie Lynn
Number of pages
Publication year
Degree date
School code
DAI-B 63/06, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
9780493707808, 0493707808
HogenEsch, Harm
Purdue University
University location
United States -- Indiana
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.